Biosimilar Candidates

Formycon Development Pipeline

Formycon currently has four biosimilar candidates in development. In addition to the pembrolizumab biosimilar candidate FYB206 and the dupilumab biosimilar candidate FYB208, these include the two undisclosed biosimilar candidates FYB209 and FYB210. Both belong to the indication area of immunology.